Evercore Downgrades Health Catalyst to In Line, Shares Drop 4%
Evercore ISI downgraded Health Catalyst (NASDAQ:HCAT) from Outperform to In Line and lowered its price target from $6.00 to $4.00, citing rising uncertainties around the company’s near- and long-term outlook. As a result, the company’s shares dropped around 4% intra-day today.
While shares have already experienced a notable decline in 2024, Evercore believes further downside risk remains, particularly due to challenges in the company’s earnings and revenue trajectory. The updated price target reflects a valuation of 8x estimated 2025 EBITDA.
In the short term, Evercore highlights several factors likely to pressure results. These include transitional costs related to the company’s exit from its unprofitable ambulatory TEMS pilot program and the near-term margin drag associated with onboarding 10 new platform clients in Q1. While both moves could support margin recovery later in the year, they are expected to weigh on first-quarter performance.
Looking further out, the firm notes that although hospital IT spending remains positive, it has softened from previous highs. Additionally, macro risks are beginning to surface, including the potential for reduced Medicaid coverage and increased expenses tied to tariffs on medical supplies and pharmaceuticals. These pressures may limit revenue growth while compressing margins.
Evercore acknowledges that Health Catalyst could benefit from initiatives like Ignite platform migrations and improved TEMS profitability. However, these gains may only partially offset the broader financial drag.
| Symbol | Price | %chg |
|---|---|---|
| 2413.T | 1895.5 | 0 |
| IKS.BO | 1597.9 | 0 |
| IKS.NS | 1595 | -0.13 |
| 4483.T | 3714 | 0 |
Evercore Downgrades Health Catalyst to In Line, Shares Drop 4%
Evercore ISI downgraded Health Catalyst (NASDAQ:HCAT) from Outperform to In Line and lowered its price target from $6.00 to $4.00, citing rising uncertainties around the company’s near- and long-term outlook. As a result, the company’s shares dropped around 4% intra-day today.
While shares have already experienced a notable decline in 2024, Evercore believes further downside risk remains, particularly due to challenges in the company’s earnings and revenue trajectory. The updated price target reflects a valuation of 8x estimated 2025 EBITDA.
In the short term, Evercore highlights several factors likely to pressure results. These include transitional costs related to the company’s exit from its unprofitable ambulatory TEMS pilot program and the near-term margin drag associated with onboarding 10 new platform clients in Q1. While both moves could support margin recovery later in the year, they are expected to weigh on first-quarter performance.
Looking further out, the firm notes that although hospital IT spending remains positive, it has softened from previous highs. Additionally, macro risks are beginning to surface, including the potential for reduced Medicaid coverage and increased expenses tied to tariffs on medical supplies and pharmaceuticals. These pressures may limit revenue growth while compressing margins.
Evercore acknowledges that Health Catalyst could benefit from initiatives like Ignite platform migrations and improved TEMS profitability. However, these gains may only partially offset the broader financial drag.
Health Catalyst, Inc. (NASDAQ: HCAT) Overview: Strategic Partnerships and Market Position
- Sean Dodge from RBC Capital sets a price target of $7 for HCAT, indicating a potential increase.
- Health Catalyst announces a multi-year partnership with OrthoNebraska to utilize its Ignite™ platform for improving patient outcomes.
- The collaboration with Databricks aims to enhance healthcare data sharing and analytics, showcasing Health Catalyst's commitment to innovation.
Health Catalyst, Inc. (NASDAQ:HCAT) is a key player in the healthcare technology sector, providing data and analytics solutions to healthcare organizations. The company focuses on improving patient outcomes and operational efficiency through its advanced platforms. Health Catalyst faces competition from other data and analytics firms, but its strategic partnerships and innovative solutions set it apart.
On January 14, 2025, Sean Dodge from RBC Capital set a price target of $7 for HCAT. At that time, the stock was trading at $6.98, indicating a modest potential increase of 0.29%. This price target reflects confidence in Health Catalyst's strategic initiatives and partnerships, which are expected to drive growth and enhance its market position.
Health Catalyst recently announced a multi-year partnership with OrthoNebraska, a leading orthopedic care provider. OrthoNebraska will use Health Catalyst Ignite™, a data and analytics ecosystem, to improve patient outcomes and operational efficiency. This collaboration highlights Health Catalyst's commitment to providing healthcare organizations with tools for data-driven decision-making.
Additionally, Health Catalyst has partnered with Databricks to enhance healthcare data sharing and analytics. This collaboration will integrate Databricks' Delta Sharing with Health Catalyst's Ignite™ platform, offering a secure and configurable solution for healthcare entities. This initiative aims to accelerate insights and provide healthcare-ready data, further strengthening Health Catalyst's offerings.
Currently, HCAT is priced at $5.90, reflecting a decrease of 9.09% from its previous value. The stock has fluctuated between $5.84 and $6.60 during the day, with a market capitalization of approximately $359 million. Despite recent volatility, Health Catalyst's strategic partnerships and innovative solutions position it well for future growth.
Health Catalyst, Inc. (NASDAQ: HCAT) Overview: Strategic Partnerships and Market Position
- Sean Dodge from RBC Capital sets a price target of $7 for HCAT, indicating a potential increase.
- Health Catalyst announces a multi-year partnership with OrthoNebraska to utilize its Ignite™ platform for improving patient outcomes.
- The collaboration with Databricks aims to enhance healthcare data sharing and analytics, showcasing Health Catalyst's commitment to innovation.
Health Catalyst, Inc. (NASDAQ:HCAT) is a key player in the healthcare technology sector, providing data and analytics solutions to healthcare organizations. The company focuses on improving patient outcomes and operational efficiency through its advanced platforms. Health Catalyst faces competition from other data and analytics firms, but its strategic partnerships and innovative solutions set it apart.
On January 14, 2025, Sean Dodge from RBC Capital set a price target of $7 for HCAT. At that time, the stock was trading at $6.98, indicating a modest potential increase of 0.29%. This price target reflects confidence in Health Catalyst's strategic initiatives and partnerships, which are expected to drive growth and enhance its market position.
Health Catalyst recently announced a multi-year partnership with OrthoNebraska, a leading orthopedic care provider. OrthoNebraska will use Health Catalyst Ignite™, a data and analytics ecosystem, to improve patient outcomes and operational efficiency. This collaboration highlights Health Catalyst's commitment to providing healthcare organizations with tools for data-driven decision-making.
Additionally, Health Catalyst has partnered with Databricks to enhance healthcare data sharing and analytics. This collaboration will integrate Databricks' Delta Sharing with Health Catalyst's Ignite™ platform, offering a secure and configurable solution for healthcare entities. This initiative aims to accelerate insights and provide healthcare-ready data, further strengthening Health Catalyst's offerings.
Currently, HCAT is priced at $5.90, reflecting a decrease of 9.09% from its previous value. The stock has fluctuated between $5.84 and $6.60 during the day, with a market capitalization of approximately $359 million. Despite recent volatility, Health Catalyst's strategic partnerships and innovative solutions position it well for future growth.
